Skip to main content
Journal ArticleOPEN ACCESS

Health Economic Evaluation of Treating Anemia in Cancer Patients Receiving Chemotherapy: A Study in Belgian Hospitals

  • Spaepen E
  • Demarteau N
  • Van Belle S
  • et al.
The Oncologist (2008) 13(5) 596-607
DOI: 10.1634/theoncologist.2007-0219
7Citations
Citations of this article
22Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Erythropoiesis-stimulating agents (ESAs) are used in chemotherapy-induced anemia (CIA) with the goal of improving quality of life and preventing RBC transfusions. This retrospective database study compared the three currently available ESAs, epoetin alfa (EPO-A), epoetin beta (EPO-B), and darbepoetin alfa (DARB), regarding costs and outcomes.

Cite

CITATION STYLE

APA

Spaepen, E., Demarteau, N., Van Belle, S., & Annemans, L. (2008). Health Economic Evaluation of Treating Anemia in Cancer Patients Receiving Chemotherapy: A Study in Belgian Hospitals. The Oncologist, 13(5), 596–607. https://doi.org/10.1634/theoncologist.2007-0219

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free